Tipsheet
What matters at India’s listed companies
M&A · Pharmaceuticals · Micro cap

Beryl Drugs promoter crosses 10% with small open-market buy

Sudhir Sethi picked up 6,950 shares, lifting his stake from 9.915% to 10.055%. The ₹12 cr nano-cap sees a modest signal of promoter confidence.


Mkt cap₹11.92 cr
P/E28.04×
ROE6.09%
Debt / eq.0.43
10.055% Promoter stake after purchase

What's new

  • Promoter Sudhir Sethi bought 6,950 shares on 25 June 2026 via open market, crossing the 10% ownership threshold.
  • His stake rose from 9.915% to 10.055%, a net increase of 0.14% of equity.
  • The acquisition value is about 1.37% of the company's ₹12 cr market cap, passing the nano-cap materiality mark.

Why this matters

Crossing 10% triggers disclosure under SEBI Takeover Regulations and signals the promoter is willing to increase skin in the game. For a ₹12 cr nano-cap with thin trading, even a small purchase can be meaningful, though the absolute quantum limits the likely price impact.

What we're watching

  • Whether Sethi continues the incremental buying pattern seen in recent weeks.
  • Any reaction in the thinly traded stock over the next few sessions.
  • Upcoming quarterly results for signs of operational improvement.

The full read

Beryl Drugs promoter Sudhir Sethi bought 6,950 shares on June 25, lifting his stake from 9.915% to 10.055% of the 50,71,700 equity shares. The acquisition, worth about 1.37% of the ₹12 cr market cap, crosses the 10% threshold under SEBI Takeover Regulations. The increase is tiny — just 0.14% of equity. It follows a pattern of incremental buying. Still, for a stock with thin liquidity, it is a modest vote of confidence from a promoter who could have deployed capital elsewhere. The absolute quantum limits price impact, but the signal is what matters.

Questions answered

Why does crossing 10% trigger a SEBI disclosure?
Under the SEBI Takeover Regulations, any promoter crossing the 10% threshold must disclose the acquisition to the exchanges. It is a regulatory requirement to track ownership changes near significant thresholds.
How material is this purchase given the company's size?
The 6,950 shares were bought for roughly 1.37% of Beryl Drugs' ₹12 cr market cap, crossing the 1% nano-cap materiality threshold. While small in absolute terms, it is a non-trivial increase for a promoter in a tiny stock.
Does this change the company's fundamentals?
No. The purchase has no direct impact on earnings, revenue, or operations. It is a signal of promoter confidence but does not alter the company's financial trajectory.
Could this lead to a takeover bid?
Unlikely. The increase is only 0.14% and the total promoter stake remains below 15%. There is no indication of an open offer or change in control.
Mentioned: Sudhir Sethi · 10% threshold · ₹12 cr market cap
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Beryl Drugs Ltd.

Pharmaceuticals
₹11 cr
P/E 25.32×

Latest quarter · Mar 2026

Sales₹5 cr
Net profit₹1 cr
Op. margin+24.5%
EPS₹1.11

Strength & growth

Debt / equity0.43×
Current ratio2.08×
Sales CAGR+3.7%
EPS CAGR+7.9%